

## Bucillamine

**Chemical Properties**

CAS No.:	65002-17-7
Formula:	C7H13NO3S2
Molecular Weight:	223.31
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).

**Biological Description**

Description	Bucillamine is an antirheumatic agent. Its activity is mediated by the two thiol groups in the molecule. Research done in USA showed positive transplant preservation properties.
-------------	---

**Solubility Information**

Solubility	DMSO: Soluble ( < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.478 mL	22.390 mL	44.781 mL
5 mM	0.896 mL	4.478 mL	8.956 mL
10 mM	0.448 mL	2.239 mL	4.478 mL
50 mM	0.090 mL	0.448 mL	0.896 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Matsuno H, Okada M, Sakai Y, Abe C, Katayama K, Sagawa A, Yamasaki K, Kondo M, Funahashi K, Matsubara T. The Usefulness of a New Triple Combination Treatment Utilizing methotrexate, salazosulfapyridine, and bucillamine in Rheumatoid Arthritis. *Mod Rheumatol*. 2015 Jun 8:1-20. [Epub ahead of print] PubMed PMID: 26052803.
2. Manabe S, Banno M, Nakano M, Fujii T, Fujiwara M, Kita Y, Nitta K, Hatano M. Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review. *Case Rep Nephrol Dial*. 2014 Oct 29;5(1):30-8. doi: 10.1159/000368826. eCollection 2015 Jan-Apr. PubMed PMID: 25849672; PubMed Central PMCID: PMC4294451.
3. Kim SJ, Ho Hur J, Park C, Kim HJ, Oh GS, Lee JN, Yoo SJ, Choe SK, So HS, Lim DJ, Moon SK, Park R. Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes. *Exp Mol Med*. 2015 Feb 20;47:e142. doi: 10.1038/emm.2014.112. PubMed PMID: 25697147; PubMed Central PMCID: PMC4346486.
4. Katayama K, Okubo T, Sato T, Ito H, Fukai R, Baba H. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. *Mod Rheumatol*. 2015 Jan;25(1):50-5. doi: 10.3109/14397595.2014.924385. Epub 2014 Jul 1. PubMed PMID: 24983407.

**Inhibitors · Natural Compounds · Compound Libraries**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.**

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481